Latest Breaking News On - European bone marrow transplant society - Page 1 : comparemela.com

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGlasgow cityAvinash desaiActimaba national cancer instituteExchange commissionEuropean bone marrow transplant societyActinium pharmaceuticals incActinium pharmaceuticalsAntibody radiation conjugatesComplete remissionOvercomes high riskScottish event campusChief medical officerNorth africanAnnual meetingNational cancer institute

Actinium s Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up

Actinium Pharmaceuticals, Inc. (ATNM), Monday announced that its Iomab-B Phase 3 SIERRA trial results demonstrated survival benefit in high-risk relapsed or refractory acute myeloid leukemia patients with TP53 mutations.

Glasgow cityUnited kingdomActinium pharmaceuticals incEuropean bone marrow transplant societyNew york stock exchangeYork stock exchangeActinium pharmaceuticalsIomabb phaseNew york stock